TEVA Q3 2020 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.0B-6.7% YoY

Gross Profit

$1.9B46.6% margin

Operating Income

-$4.3B-109.2% margin

Net Income

-$4.3B-109.3% margin

EPS (Diluted)

$-3.97

QoQ Revenue Growth

+2.8%

Cash Flow

Operating Cash Flow

$307M

Free Cash Flow

$164M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$49.7B

Total Liabilities

$39.1B

Stockholders' Equity

$9.6B

Cash & Equivalents

$1.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.0B	$4.3B	-6.7%
Gross Profit	$1.9B	$1.8B	+1.3%
Operating Income	-$4.3B	-$81M	-5260.5%
Net Income	-$4.3B	-$314M	-1285.0%

Revenue Segments

Product

$3.4B86%

Distribution Service

$350M9%

Product and Service, Other

$174M4%

License

$27M1%

Geographic Segments

North America Segment

$2.0B55%

Europe Segment

$1.1B30%

International Markets

$529M14%